ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,379, issued on Oct. 7, was assigned to The University of Chicago (Chicago).
"BTK mutation and ibrutinib resistance" was invented by Y. Lynn Wang (Chicago).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are mutations in Bruton's Tyrosine Kinase (BTK) that confer resistance to treatment with a BTK inhibitors, such as Ibrutinib, and compositions and methods for the treatment, diagnosis, and characterization of BTK-inhibitor-resistant cancers."
The patent was filed on Aug. 11, 2021, under Application No. 17/399,831.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect...